Quantcast
Channel: All News Releases
Viewing all articles
Browse latest Browse all 3224

Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM

$
0
0

National SURVIVE study to proceed in patients with glioblastoma following interim analysis BUFFALO, N.Y., May 9, 2025 /PRNewswire-PRWeb/ -- Roswell Park Comprehensive Cancer Center today announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue...


Viewing all articles
Browse latest Browse all 3224

Trending Articles